Pharmacological Adjuvants to Limit Erythropoietin Stimulating Agents Exposure
نویسندگان
چکیده
Anemia in chronic kidney disease (CKD) is common, causing morbidity and mortality, and is primarily due to reduced erythropoietin (EPO) release and, to a lesser degree, shortened red cell survival. Erythropoietin Stimulating Agents like epoetin Alfa and darbepoetin alpha are used commonly to treat this form of anemia. Recent evidence suggests increased morbidity and mortality associated with higher hemoglobin in the setting of these agents use. Whether these complications are due to higher dose of erythropoietin or its resistance (i.e., inflammation), or achieving a higher hemoglobin remains unclear. Tightening restrictions on these agents has led to increase interest in the use of non-ESA adjuvants to improve erythropoiesis. This review will highlight the most promising of these agents.
منابع مشابه
O-6: Pharmacological and Molecular Evaluation of Herbal Drugs in The Treatment of Sexual Dysfunction and As Stimulating Agents
Background: Vajikarana herbs from Ayurveda are known to enhance the sexual performance in folklore. The objective is to evaluate their effect by molecular and pharmacological screening. Materials and Methods: In the present study, the effect of four Vajikaran Rasayana herbs on penile erection, sperm count, seminal fructose content in vivo and nitric oxide (NO) release in vitro was assessed. Pen...
متن کاملp-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes.
Serum erythropoietin level less than 100U/L and a transfusion requirement of less than 2 units per month are the best predictive factors for response to treatment by erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes. To investigate the factors influencing the response to erythropoiesis-stimulating agents, we enrolled 127 low/int-1 myelodysplastic syndrome patients at diag...
متن کاملThe role of erythropoietin (EPO) and erythropoiesis stimulating agents (ESAs) in tumor progression
متن کامل
Darbepoietin-alfa has comparable erythropoietic stimulatory effects to recombinant erythropoietin whilst preserving the bone marrow microenvironment.
Erythropoiesis stimulating agents are widely used for the treatment of anemia. Recently, we reported erythroid expansion with impaired B lymphopoiesis and loss of trabecular bone in C57BL/6 mice following ten days of treatment with low-dose short acting recombinant human erythropoietin. We have assessed erythropoietin against longer-acting darbepoietin-alfa at a comparable erythroid stimulatory...
متن کاملPharmacologic Adjuvants to Reduce Erythropoietin Therapy Dose in Anemia of Chronic Kidney Disease and End Stage Renal Disease
Anemia is one of the leading causes of morbidity in chronic renal failure.1 Chronic kidney disease (CKD) associated anemia is largely due to reduced erythropoietin (EPO) release and, to a lesser degree, to shortened red cell survival.2 To overcome EPO deficiency in this population, the development and administration of erythropoiesis-stimulating agents (ESAs) such as recombinant human EPO and d...
متن کامل